[시장보고서]올리고뉴클레오티드 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

올리고뉴클레오티드 CDMO 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Oligonucleotide CDMO Market Size, Share & Trends Analysis Report By Service, By Type, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1908235

리서치사 : Grand View Research

발행일 : 2025년 12월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,626,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,076,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,976,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

올리고뉴클레오티드 CDMO 시장 개요

세계의 올리고뉴클레오티드 CDMO 시장 규모는 2024년에 9억 1,178만 달러로 추정되며, 2033년에 31억 6,897만 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 CAGR 14.98%로 성장할 것으로 예상됩니다. 이 시장은 안티센스 및 siRNA 치료제의 임상 파이프라인 증가, 백신 이외의 mRNA 기반 치료제의 채택 확대, 제조의 복잡성을 줄이기 위한 생명공학 기업들의 아웃소싱 증가에 의해 주도되고 있습니다.

또한, RNA 기반 및 안티센스 치료제의 파이프라인이 증가함에 따라 생산 확장을 지원하는 전문 제조 파트너의 필요성이 증가하고 있습니다. 이러한 후보물질이 후기 임상 단계에 진입함에 따라, 스폰서 기업들은 생산능력의 제약과 순도 요구사항의 고도화에 직면하고 있으며, 확장 가능하고 규정을 준수하는 생산을 위해 경험이 풍부한 위탁개발생산(CDMO)으로의 전환이 진행되고 있습니다. 여러 개발 단계에 걸쳐 일관된 GMP 등급의 재료가 필요하다는 점도 아웃소싱의 추세를 더욱 강화하여 이 부문에서 위탁 제조 서비스의 꾸준한 보급을 뒷받침하고 있습니다.

또한, 올리고뉴클레오티드 화학이 복잡해지면서 고도의 합성 플랫폼과 분석 역량이 필요하지만, 많은 신생 바이오기업들이 자체적으로 이러한 역량을 개발할 수 없다는 점도 시장 성장에 기여하고 있습니다. 결합 올리고, 첨단 전달 시스템, 장쇄 배열과 같은 몇 가지 발전은 추가적인 기술적 과제를 추가하고 있으며, 이로 인해 기업들은 입증된 전문성을 갖춘 CDMO에 의존하게 되었습니다. 따라서 높은 수율, 낮은 불순물 프로파일, 유연한 배치 스케일링을 실현할 수 있는 기술적으로 진보된 공급업체는 전체 개발 범위에서 매우 중요해지고 있습니다.

지역별 시장 대시보드
세계 지역별 시장 개요
시장 규모와 예측, 동향 분석(2021-2033년) :
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
- 오만
- 카타르

제9장 경쟁 구도

기업 분류
- 시장 리더
- 신흥 기업
올리고뉴클레오티드 CDMO 시장 점유율 분석, 2024년
기업 개요
- PolyPeptide Group
- STA Pharmaceutical Co. Ltd.
- Bachem
- Creative Peptides
- Aurigene Pharmaceutical Services Ltd.
- Merck KGaA
- EUROAPI
- Curia Global, Inc.
- CordenPharm
- Sylentis, S.A.

KSM

영문 목차

영문목차

Oligonucleotide CDMO Market Summary

The global oligonucleotide CDMO market size was estimated at USD 911.78 million in 2024 and is projected to reach USD 3,168.97 million by 2033, growing at a CAGR of 14.98% from 2025 to 2033. The market is driven by the rising clinical pipeline of antisense and siRNA therapies, growing adoption of mRNA-based therapeutics beyond vaccines, and increasing outsourcing by biotech firms to reduce manufacturing complexity.

In addition, the increasing number of pipeline of RNA-based and antisense therapeutics is driving the need for specialized manufacturing partners to help them scale production. As these candidates progress into late-stage clinical trials, sponsors encounter capacity constraints and heightened purity requirements, prompting a shift toward experienced contract development and manufacturing organizations (CDMOs) for scalable and compliant production. The need for consistent GMP-grade materials across multiple development phases further strengthens outsourcing trends and supports the steady uptake of contract manufacturing services in this domain.

Furthermore, the growing complexity of oligonucleotide chemistry, which requires sophisticated synthesis platforms and analytical capabilities that many emerging biotech firms cannot develop internally is also contributing to market growth. Several advancements such as conjugated oligos, advanced delivery systems, and long-chain sequences is adding additional technical challenges which is encouraging companies to depend on CDMOs with proven expertise. Thus, technologically advanced providers that can deliver high yield, reduced impurity profiles, and flexible batch scaling are becoming crucial across the development range.

Global Oligonucleotide CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oligonucleotide CDMO market report based on service, type, application, end use, and region:

Service Outlook (Revenue, USD Million, 2021 - 2033)
Contract Manufacturing
Contract Development
Type Outlook (Revenue, USD Million, 2021 - 2033)
Antisense Oligonucleotides
Small Interfering RNA
Other Oligonucleotides
Application Outlook (Revenue, USD Million, 2021 - 2033)
Therapeutic
Research
Diagnostic
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Pharmaceutical & Biopharmaceutical Companies
Diagnostic Companies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Landscape Insights

Chapter 3. Oligonucleotide CDMO Market: Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Oligonucleotide CDMO Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunities
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Supply Chain Analysis
3.7. Market Analysis Tools
- 3.7.1. Porter's Five Forces Analysis
- 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Oligonucleotide CDMO Market: Service Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Oligonucleotide CDMO Market Service Movement Analysis
4.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
4.4. Contract Manufacturing
- 4.4.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.5. Contract Development
- 4.5.1. Contract Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oligonucleotide CDMO Market: Type Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Oligonucleotide CDMO Market Type Movement Analysis
5.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
5.4. Antisense Oligonucleotides
- 5.4.1. Antisense Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Small Interfering RNA
- 5.5.1. Small Interfering RNA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Other Oligonucleotides
- 5.6.1. Other Oligonucleotides Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oligonucleotide CDMO Market: Application Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Oligonucleotide CDMO Market Application Movement Analysis
6.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Therapeutic
- 6.4.1. Therapeutic Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Research
- 6.5.1. Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Diagnostic
- 6.6.1. Diagnostic Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oligonucleotide CDMO Market: End Use Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Global Oligonucleotide CDMO Market End Use Movement Analysis
7.3. Global Oligonucleotide CDMO Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
7.4. Pharmaceutical and Biopharmaceutical Companies
- 7.4.1. Pharmaceutical and Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Diagnostic Companies
- 7.5.1. Diagnostic Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Others
- 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Oligonucleotide CDMO Market: Regional Estimates & Trend Analysis by Product, Service, End Use

8.1. Regional Market Dashboard
8.2. Global Regional Market Snapshot
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
- 8.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. Competitive Scenario
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. Competitive Scenario
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. Competitive Scenario
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
- 8.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. Competitive Scenario
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. Competitive Scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. Competitive Scenario
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. Competitive Scenario
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. Competitive Scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. Competitive Scenario
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. Competitive Scenario
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. Competitive Scenario
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. Competitive Scenario
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. Competitive Scenario
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. Competitive Scenario
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. Competitive Scenario
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. Competitive Scenario
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. Competitive Scenario
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. Competitive Scenario
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. Competitive Scenario
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. MEA
- 8.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. Competitive Scenario
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. Competitive Scenario
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. Competitive Scenario
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. Competitive Scenario
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.6. Oman
  - 8.8.6.1. Key Country Dynamics
  - 8.8.6.2. Competitive Scenario
  - 8.8.6.3. Regulatory Framework
  - 8.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.7. Qatar
  - 8.8.7.1. Key Country Dynamics
  - 8.8.7.2. Competitive Scenario
  - 8.8.7.3. Regulatory Framework
  - 8.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company Categorization
- 9.1.1. Market Leaders
- 9.1.2. Emerging Players
9.2. Oligonucleotide CDMO Market Share Analysis, 2024
9.3. Company Profiles
- 9.3.1. PolyPeptide Group
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Financial Performance
  - 9.3.1.3. Product/Service Benchmarking
  - 9.3.1.4. Strategic Initiatives
- 9.3.2. STA Pharmaceutical Co. Ltd.
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Financial Performance
  - 9.3.2.3. Product/Service Benchmarking
  - 9.3.2.4. Strategic Initiatives
- 9.3.3. Bachem
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Financial Performance
  - 9.3.3.3. Product/Service Benchmarking
  - 9.3.3.4. Strategic Initiatives
- 9.3.4. Creative Peptides
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Financial Performance
  - 9.3.4.3. Product/Service Benchmarking
  - 9.3.4.4. Strategic Initiatives
- 9.3.5. Aurigene Pharmaceutical Services Ltd.
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Financial Performance
  - 9.3.5.3. Product/Service Benchmarking
  - 9.3.5.4. Strategic Initiatives
- 9.3.6. Merck KGaA
  - 9.3.6.1. Company Overview
  - 9.3.6.2. Financial Performance
  - 9.3.6.3. Product/Service Benchmarking
  - 9.3.6.4. Strategic Initiatives
- 9.3.7. EUROAPI
  - 9.3.7.1. Company Overview
  - 9.3.7.2. Financial Performance
  - 9.3.7.3. Product/Service Benchmarking
  - 9.3.7.4. Strategic Initiatives
- 9.3.8. Curia Global, Inc.
  - 9.3.8.1. Company Overview
  - 9.3.8.2. Financial Performance
  - 9.3.8.3. Product/Service Benchmarking
  - 9.3.8.4. Strategic Initiatives
- 9.3.9. CordenPharm
  - 9.3.9.1. Company Overview
  - 9.3.9.2. Financial Performance
  - 9.3.9.3. Product/Service Benchmarking
  - 9.3.9.4. Strategic Initiatives
- 9.3.10. Sylentis, S.A.
  - 9.3.10.1. Company Overview
  - 9.3.10.2. Financial Performance
  - 9.3.10.3. Product/Service Benchmarking
  - 9.3.10.4. Strategic Initiatives

한글목차

올리고뉴클레오티드 CDMO 시장 개요

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 올리고뉴클레오티드 CDMO 시장 : 변수, 동향, 범위

제4장 올리고뉴클레오티드 CDMO 시장 : 서비스별, 추정·동향 분석

제5장 올리고뉴클레오티드 CDMO 시장 : 유형별, 추정·동향 분석

제6장 올리고뉴클레오티드 CDMO 시장 : 용도별, 추정·동향 분석

제7장 올리고뉴클레오티드 CDMO 시장 : 최종 용도별, 추정·동향 분석

제8장 올리고뉴클레오티드 CDMO 시장 : 서비스별, 최종 용도별, 지역별, 추정·동향 분석